Duncan Jason — SEC insider filings
SEC reporting owner CIK 1741553. 25 insider filings on record with FilingPulse; latest filed 2026-11-13.
Transaction summary — filings shown
Covers all 25 filings on record, filed 2020-09-10 to 2026-11-13. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 29 legs across 14 filings — 27,984 shares, $1,014,777 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 34.
- Largest priced transaction: sale of 10,000 shares @ $36.38 ($363,800) in ALBIREO PHARMA, INC., filed 2021-06-28.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| ALBIREO PHARMA, INC. (ALBO) | Chief Legal Officer and GC | 18 | — | 29 legs · 27,984 sh · $1,014,777 | 23 |
| Neumora Therapeutics, Inc. (NMRA) | See Remarks | 5 | — | — | 10 |
| enGene Therapeutics Inc. (ENGN) | Chief Legal & Admin Officer | 2 | — | — | 1 |
Insider filings — Duncan Jason
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-13 | 3 | enGene Therapeutics Inc. (ENGN) | Holdings only — no transactions reported | EDGAR |
| 2026-11-13 | 4 | enGene Therapeutics Inc. (ENGN) | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2026-08-21 | 4 | Neumora Therapeutics, Inc. (NMRA) | Grant/award (A): 375,000 (derivative) @ $0 | EDGAR |
| 2026-01-09 | 4 | Neumora Therapeutics, Inc. (NMRA) | Grant/award (A): 750,000 (derivative) @ $0 | EDGAR |
| 2025-05-30 | 4 | Neumora Therapeutics, Inc. (NMRA) | Disposition to issuer (D): 400,000 (derivative) · Disposition to issuer (D): 500,000 (derivative) · Grant/award (A): 400,000 (derivative) · Grant/award (A): 500,000 (derivative) | EDGAR |
| 2025-02-18 | 4 | Neumora Therapeutics, Inc. (NMRA) | Grant/award (A): 500,000 (derivative) @ $0 · Disposition to issuer (D): 400,000 (derivative) · Grant/award (A): 400,000 (derivative) | EDGAR |
| 2023-12-12 | 4 | Neumora Therapeutics, Inc. (NMRA) | Grant/award (A): 400,000 (derivative) @ $0 | EDGAR |
| 2023-03-02 | 4 | ALBIREO PHARMA, INC. (ALBO) | Code (U): 3,296 · Disposition to issuer (D): 15,900 (derivative) · Disposition to issuer (D): 10,063 (derivative) · Disposition to issuer (D): 24,337 (derivative) · Disposition to issuer (D): 23,700 (derivative) · Disposition to issuer (D): 37,500 (derivative) · +1 more | EDGAR |
| 2023-01-27 | 4/A | ALBIREO PHARMA, INC. (ALBO) | Grant/award (A): 55,000 @ $0 | EDGAR |
| 2023-01-25 | 4 | ALBIREO PHARMA, INC. (ALBO) | Grant/award (A): 55,000 @ $0 | EDGAR |
| 2023-01-23 | 4 | ALBIREO PHARMA, INC. (ALBO) | Sale (S): 228 @ $43.80 | EDGAR |
| 2023-01-20 | 4 | ALBIREO PHARMA, INC. (ALBO) | Sale (S): 938 @ $43.90 | EDGAR |
| 2022-10-25 | 4 | ALBIREO PHARMA, INC. (ALBO) | Sale (S): 104 @ $19.58 · Sale (S): 96 @ $19.54 · Sale (S): 456 @ $19.40 | EDGAR |
| 2022-07-25 | 4 | ALBIREO PHARMA, INC. (ALBO) | Sale (S): 106 @ $24.68 · Sale (S): 238 @ $24.45 · Sale (S): 93 @ $24.39 · Sale (S): 220 @ $23.66 | EDGAR |
| 2022-04-25 | 4 | ALBIREO PHARMA, INC. (ALBO) | Sale (S): 240 @ $33.07 · Sale (S): 103 @ $32.93 · Sale (S): 221 @ $33.44 · Sale (S): 91 @ $33.40 | EDGAR |
| 2022-01-25 | 4 | ALBIREO PHARMA, INC. (ALBO) | Sale (S): 416 @ $24.88 · Sale (S): 96 @ $25.09 · Sale (S): 1,176 @ $24.94 | EDGAR |
| 2022-01-20 | 4 | ALBIREO PHARMA, INC. (ALBO) | Grant/award (A): 10,800 @ $0 · Grant/award (A): 15,900 (derivative) @ $0 | EDGAR |
| 2021-10-25 | 4 | ALBIREO PHARMA, INC. (ALBO) | Sale (S): 95 @ $28.85 · Sale (S): 217 @ $29.21 | EDGAR |
| 2021-07-26 | 4 | ALBIREO PHARMA, INC. (ALBO) | Sale (S): 90 @ $34.13 · Sale (S): 223 @ $31.43 | EDGAR |
| 2021-06-28 | 4 | ALBIREO PHARMA, INC. (ALBO) | Option exercise (M): 9,137 @ $24.04 · Option exercise (M): 863 @ $24.67 · Sale (S): 10,000 @ $36.38 · Option exercise (M): 6,300 @ $24.67 · Sale (S): 6,300 @ $36.22 · Option exercise (M): 9,137 (derivative) @ $0 · +2 more | EDGAR |
| 2021-04-26 | 4 | ALBIREO PHARMA, INC. (ALBO) | Sale (S): 90 @ $31.75 · Sale (S): 222 @ $32.32 | EDGAR |
| 2021-04-02 | 4 | ALBIREO PHARMA, INC. (ALBO) | Sale (S): 1,426 @ $35.04 · Option exercise (M): 300 @ $24.04 · Sale (S): 300 @ $36.16 · Option exercise (M): 300 (derivative) @ $0 | EDGAR |
| 2021-01-25 | 4 | ALBIREO PHARMA, INC. (ALBO) | Grant/award (A): 5,500 @ $0 · Sale (S): 110 @ $34.62 · Grant/award (A): 23,700 (derivative) @ $0 | EDGAR |
| 2020-10-23 | 4 | ALBIREO PHARMA, INC. (ALBO) | Sale (S): 89 @ $34.71 | EDGAR |
| 2020-09-10 | 4 | ALBIREO PHARMA, INC. (ALBO) | Option exercise (M): 3,500 @ $24.04 · Sale (S): 4,000 @ $45.55 · Option exercise (M): 3,500 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-04 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1741553 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs